![]() ![]() After taking my medication for approximately 2 months I developed my tongue constantly licking my lips which resulted in not being confident public speaking the Dx of TD was given and the medications to treat were prescribed. ![]() Researchers have warned that drug manufacturers failed to provide adequate warnings about the risk of impulsive behavior on the drugs, indicating that information about the risk dates back to at least 2009, when a study found that approximately 18% of patients taking a dopamine agonist for treatment of Parkinsons disease could suffer from compulsive behavior side effects.Īlthough Abilify is a partial dopamine receptor agonists, researchers found that the same signals for gambling and other impulse control problems with Abilify were seen among users of the antipsychotic medication as well.Ībilify was prescribed to me in 2020 by my psychiatrist. However, a safety signal was also seen for Abilify gambling and impulse control problems, with at least 37 reports found specifically involving this one medication. The Parkinson’s disease drugs Mirapex and Requip were most strongly linked to incidents of impulse control problems among the dopamine receptor agonists, leading to gambling addictions and hypersexuality, and even compulsive shopping. There are six FDA-approved dopamine agonists currently on the market in the United States. In addition to concerns about the risk of tardive dyskinesia, Abilify has also been linked to reports of impulse control problems, including gambling addictions, sex addictions and other similar behavior that has been linked to a class of drugs known as dopamine receptor agonists.Ī recent study by the Institute for Safe Medication Practices, published in the medical journal JAMA Internal Medicine, found that this class of drugs was linked to impulse control problems, such as compulsive gambling, sex addiction and other issues that may have a severe impact on an individual’s life. “he Court finds that Plaintiff’s failure-to-warn claim satisfies this standard and is sufficient to survive Defendant’s … motion.” Abilify Side EffectsĪbilify (aripiprazole) was approved by the FDA in 2002, and is one of the top selling drugs in the U.S., generating sales of $7.5 billion in 2013. “Plaintiff is merely required to allege that Defendants did not adequately warn Plaintiff’s treating physician and that the inadequate warning constituted the proximate warning of Plaintiff’s injuries,” Judge Fallon ruled. ![]() While Judge Fallon did dismiss the design defect claim, he rejected the request to dismiss the failure to warn claim, allowing the tardive dyskinesia lawsuit over Abilify to move forward. In addition, the defendants maintained that the failure to warn claims should be dismissed because Jenkins failed to allege that his treating physician would not have prescribed the drug if different warnings had been provided. In a motion to dismiss filed by Bristol-Myers Squibb and Otsuka, the drug makers argue that the defective design claims fail to allege that there was a safer alternative design. Jenkins asserted two separate theories of liability, including defective design and failure to warn about the Abilify tardive dyskinesia risk. District Court for the Eastern District of Louisiana, he developed “chronic and continued restlessness and twitching of the upper and lower extremities, facial tics, jaw clenching and clucking, and constant eye blinking” in 2013, after taking the antidepressant. According to allegations raised in the complaint (PDF) filed by Jenkins pending in the U.S. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |